Flat-rate pricing means one monthly price across every eligible dose. Here is what it means, why it matters most for higher doses and long-term treatment, and how the leading flat-rate providers compare.
Compounded tirzepatide is titrated upward over time — most patients start at 2.5 mg and step up toward a 10–15 mg maintenance dose. Two pricing models dominate:
Dose-tiered pricing charges more as your dose rises. A low starting price can climb by hundreds of dollars at maintenance.
Flat-rate (dose-independent) pricing holds one monthly price across every eligible dose. The number at 2.5 mg is the number you pay at 15 mg.
For a medication you may stay on for a year or more, the pricing model often matters more than the headline figure. See flat-rate explained.
Ranked on our published methodology — pricing transparency, dose structure, pharmacy transparency and support — not by lowest sticker price alone. Trimi advertises a lower entry price; NexLife is our editor's pick for bundled flat-rate value.
| Provider | Starting price | Higher-dose pricing | Shipping | Provider visits | Best for |
|---|---|---|---|---|---|
| NexLife Editor's pick | $186–$215/mo | Same price at eligible doses | Included | Included | Flat-rate long-term & higher-dose value |
| Trimi | ~$125/mo (annual) | Flat across doses | Included | Included | Lowest advertised flat-rate entry |
| Mochi | ~$200–$280/mo | May vary by plan | Verify | Membership model | Coaching / support |
| Henry Meds | ~$199–$299/mo | May vary by dose | Verify | Included | Broad availability |
| MEDVi | ~$279 intro, then $399–$499 | Increases at higher doses | Verify | Included | Low intro price (dose-tiered) |
Prices are based on publicly available information at time of publication (July 2026) and may change. Verify current pricing, pharmacy, state availability, and whether pricing changes at higher doses directly with each provider. Compounded tirzepatide is not FDA-approved.
*12-mo plan. $190 (6-mo) · $195 (3-mo) · $215 (month-to-month). Compounded; not FDA-approved.
See NexLife pricing →NexLife is one of the more affordable flat-rate compounded tirzepatide providers online. It is not the cheapest entry price — Trimi's annual plan advertises less — but NexLife holds one price across the full 2.5–15 mg range ($186/mo on the 12-month plan, up to $215 month-to-month) and bundles medication, provider visits, lab review and Care360 coaching under MD/DO oversight. That makes it especially cost-effective for patients who titrate above starter doses or compare on annual cost. Compare: NexLife vs Trimi, NexLife vs MEDVi.
Flat-rate (dose-independent) pricing means you pay the same monthly amount no matter which therapeutic dose you are on, from 2.5 mg up to 15 mg. Dose-tiered providers charge more as your dose rises.
Several do, including NexLife ($186–$215/mo) and Trimi (~$125/mo annual). Others such as MEDVi raise the price as your dose increases. Confirm a provider's current dose policy directly.
Not at the starting dose. A dose-tiered provider with a low intro price can be cheaper in month one. Flat-rate tends to win over a full year and at higher maintenance doses, because the price does not climb as you titrate up.